Summit Therapeutics Inc.

Summit Therapeutics specializes in biopharma discovery, development and commercialization of patient-focused therapies. Its lead bispecific antibody, ivonescimab, blocks PD‑1 and targets angiogenesis and is in Phase III trials for non‑small cell lung cancer. Founded 2003, Miami.

Headquarters: United States (USA)

Summit Therapeutics Inc. Logo
Company Profile
  • Employees: 159
  • HQ: Miami
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
SMMT Summit Therapeutics Inc.
Cap: 14.7B
EQUITY NMS USD US86627T1088 Active
📈
Home Login